ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE and RENAL IMPAIRMENT

Overview

RENAL IMPAIRMENT is the #18 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 554 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE to RENAL IMPAIRMENT. This represents approximately 1.3% of all 43,023 adverse event reports for this drug.

Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE who experience renal impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

RENAL IMPAIRMENT is a less commonly reported adverse event for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, but still significant enough to appear in the safety profile.

Other Side Effects of ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

In addition to renal impairment, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE:

• BONE DENSITY DECREASED — 4,492 reports
• CHRONIC KIDNEY DISEASE — 2,605 reports
• BONE LOSS — 2,410 reports
• OSTEONECROSIS — 2,378 reports
• TOOTH LOSS — 2,247 reports
• MULTIPLE FRACTURES — 2,131 reports
• RENAL FAILURE — 2,086 reports
• OSTEOPOROSIS — 1,928 reports
• RENAL INJURY — 1,916 reports
• PAIN — 1,857 reports

Other Drugs Associated with RENAL IMPAIRMENT

The following drugs have also been linked to renal impairment in FDA adverse event reports:

Does ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE cause RENAL IMPAIRMENT?

RENAL IMPAIRMENT has been reported as an adverse event in 554 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is RENAL IMPAIRMENT with ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

RENAL IMPAIRMENT accounts for approximately 1.3% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, making it a notable side effect.

What should I do if I experience RENAL IMPAIRMENT while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

If you experience renal impairment while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages